Stock Track | Iovance Biotherapeutics Soars 31.49% on Strong Q3 Results and Pipeline Progress

Stock Track11-06

Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are soaring 31.49% in Thursday's trading session following the release of the company's impressive third-quarter 2025 financial results and positive updates on its pipeline progress.

The biotechnology firm reported a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.

Iovance also highlighted several key developments in its pipeline. The company reported positive interim data from the IOV-LUN-202 clinical trial, demonstrating a potentially best-in-class clinical profile for lifileucel in previously treated advanced nonsquamous non-small cell lung cancer (NSCLC). The objective response rate was 26%, and the median duration of response was not reached after more than 25 months of follow-up. Additionally, Iovance reaffirmed its full-year 2025 revenue guidance within the range of $250 to $300 million, boosting investor confidence in the company's growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126199065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126199065","market":"us","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Soars 31.49% on Strong Q3 Results and Pipeline Progress","media":"Stock Track","content":"<p>Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are soaring 31.49% in Thursday's trading session following the release of the company's impressive third-quarter 2025 financial results and positive updates on its pipeline progress.</p>\n\n<p>The biotechnology firm reported a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.</p>\n\n<p>Iovance also highlighted several key developments in its pipeline. The company reported positive interim data from the IOV-LUN-202 clinical trial, demonstrating a potentially best-in-class clinical profile for lifileucel in previously treated advanced nonsquamous non-small cell lung cancer (NSCLC). The objective response rate was 26%, and the median duration of response was not reached after more than 25 months of follow-up. Additionally, Iovance reaffirmed its full-year 2025 revenue guidance within the range of $250 to $300 million, boosting investor confidence in the company's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Soars 31.49% on Strong Q3 Results and Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Soars 31.49% on Strong Q3 Results and Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are soaring 31.49% in Thursday's trading session following the release of the company's impressive third-quarter 2025 financial results and positive updates on its pipeline progress.</p>\n\n<p>The biotechnology firm reported a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.</p>\n\n<p>Iovance also highlighted several key developments in its pipeline. The company reported positive interim data from the IOV-LUN-202 clinical trial, demonstrating a potentially best-in-class clinical profile for lifileucel in previously treated advanced nonsquamous non-small cell lung cancer (NSCLC). The objective response rate was 26%, and the median duration of response was not reached after more than 25 months of follow-up. Additionally, Iovance reaffirmed its full-year 2025 revenue guidance within the range of $250 to $300 million, boosting investor confidence in the company's growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1126199065","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126199065","pubTimestamp":1762442481,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are soaring 31.49% in Thursday's trading session following the release of the company's impressive third-quarter 2025 financial results and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"个股追踪|Iovance Biotherapeutics飙升31.49%，得益于强劲的Q3业绩和管线进展","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) are soaring 31.49% in Thursday's trading session following the release of the company's impressive third-quarter 2025 financial results and positive updates on its pipeline progress.\nThe biotechnology firm reported a 13% increase in total product revenue compared to the previous quarter, reaching approximately $68 million. This growth was primarily driven by U.S. Amtagvi sales of around $58 million and global Proleukin revenue of about $10 million. Notably, the company's gross margin improved to 43%, which management attributed to enhanced execution and operational efficiency.\nIovance also highlighted several key developments in its pipeline. The company reported positive interim data from the IOV-LUN-202 clinical trial, demonstrating a potentially best-in-class clinical profile for lifileucel in previously treated advanced nonsquamous non-small cell lung cancer (NSCLC). The objective response rate was 26%, and the median duration of response was not reached after more than 25 months of follow-up. Additionally, Iovance reaffirmed its full-year 2025 revenue guidance within the range of $250 to $300 million, boosting investor confidence in the company's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126199065","isCrawlerRequest":true}